近期，北京市西城区市场监管局月坛街道市场监管所对药品零售（连锁）药店开展处方药销售检查行动。检查中，执法人员要求 药品经营单位严格落实处方药销售管理规定，做好处方审核与留存工作，定期核对处方信息与销售记录，严禁处方药开架自选陈 列销售。本报记者董芳忠摄影报道 （来源：中国消费者报） ...

（编辑 丛可心） 证券日报网讯 12月17日，健之佳在互动平台回答投资者提问时表示，公司以顾客需求为核心，聚焦主 业，长期专注于差异化定位的药品零售、便利零售行业，持续强化核心竞争力。面对政策影响、医药消 费低迷、行业短期压力和中期转型挑战，公司迅速调整短期经营策略，坚决转型，聚焦存量门店效率以 争取市场份额。非常感谢投资者对公司的关注以及提出的转型建议，一方面对跨行业、跨界进入不熟 悉、公司尚未具备优势的竞争性领域，公司持开放但审慎的态度评估风险及自身能力潜力，另一方面， 坚决推进转型工作，以提升店效、人效。 ...

齐鲁晚报·齐鲁壹点 李梓博 日前，"2025淄博企业100强""2025淄博制造业企业100强""2025淄博服务业企业30强"名单公布。 据悉，为引导淄博企业加快做大做强做优，打造更多具有国内国际一流竞争力的龙头骨干企业，经企业 自愿申报、区县推荐、市级审核、部门征询意见、社会公示等程序，最终确定上述名单。 两年前，山东信宏仁医药迎来品牌升级，由单一药品零售企业升级为健康产业集团。与此同时，山东神 奇医药产业园建成投用，该项目总建筑面积66500平方米，总投资约3亿元，主要建设内容包括仓储中 心、研发中心、质检中心、综合服务区及生产生活配套设施等。 其中，山东信宏仁医药有限公司入围"2025淄博企业100强""2025淄博服务业企业30强"名单。 未来，山东信宏仁医药将继续坚持"诚信、精进、利他、客户至上"的核心价值观，秉承"帮助患者解除 病痛、帮助员工成长、奉献社会"的企业精神，不断提升企业核心竞争力，心怀感恩和恭敬之心，不忘 初衷，为人民群众提供全方位全生命周期的健康管理服务，服务百姓健康100年，为健康中国建设贡献 力量。 这是这家区域药品零售龙头企业首次入围该榜单，在"2025淄博企业100强"名单 ...

龙丰集团的资产负债表显示，公司资产结构正在经历显著调整。非流动资产从2023年的8.91亿港元持续下降至2025上半年的5.77亿港元，降幅达35.2%。与 此同时，流动资产则从2.88亿港元大幅增长至7.35亿港元，增幅达155.2%。 11月28日，扎根香港30年的龙丰集团控股有限公司（简称"龙丰集团"）正式向香港联合交易所递交主板上市申请，星展亚洲融资担任独家保荐人。 根据弗若斯特沙利文的报告，龙丰集团以5.2%的市场份额成为香港最大药品零售商，按平均单店SKU计算亦为香港最大药妆零售商。这一双重"最大"的头衔 背后，是其对香港消费者需求的深刻理解和长达三十年的精准布局。 三年从亏损到盈利的逆袭背后 招股书显示，作为以"龙丰"品牌营运的连锁零售药妆百货营运商，该公司通过29间香港零售店铺及多平台线上渠道开展业务，根据弗若斯特沙利文报告，其 2024年以5.2%市场份额成为香港最大药品零售商，按平均单店SKU计亦为香港最大药妆零售商。 业务布局方面，龙丰集团线下门店网络覆盖香港战略位置，5间位于香港岛、10间位于九龙、14间位于新界，多数为街铺形式。其中旺角家乐坊旗舰店总楼 面面积约17,500平方呎，为 ...

11月28日，扎根香港30年的龙丰集团控股有限公司(简称"龙丰集团")正式向香港联合交易所递交主板上市申请，星展亚洲融资担任独家保荐人。 根据弗若斯特沙利文的报告，龙丰集团以5.2%的市场份额成为香港最大药品零售商，按平均单店SKU计算亦为香港最大药妆零售商。这一双重"最大"的头衔 背后，是其对香港消费者需求的深刻理解和长达三十年的精准布局。 三年从亏损到盈利的逆袭背后 盈利方面，2023财年，公司尚处于亏损状态，税前溢利为负2520.7万港元；而到了2025财年，税前溢利已达2.18亿港元，实现了惊人的逆转。2026财年第一 季延续了这一良好势头，税前溢利5993.2万港元，同比增长超过100%。 龙丰集团的资产负债表显示，公司资产结构正在经历显著调整。非流动资产从2023年的8.91亿港元持续下降至2025上半年的5.77亿港元，降幅达35.2%。与 此同时，流动资产则从2.88亿港元大幅增长至7.35亿港元，增幅达155.2%。 值得关注的是，报告期内，龙丰集团的流动负债净额持续为负，分别为-7.94亿元、-6.74亿元、-6.44亿元及-3.32亿港元。这意味这公司存在短期偿债风险。 即流动资产长期无 ...

Core Insights - The National Health Commission reported that 17 provinces in China are experiencing high levels of influenza activity, with a positive rate of 51% for flu virus tests among patients with flu-like symptoms [1] - In response to the urgent need for respiratory health protection during the flu season, Kunming Pharmaceutical Group and Yixintang Pharmaceutical initiated the "Clear Lung Action" campaign to promote public awareness of respiratory health and scientific prevention methods [1] Group 1 - The "Clear Lung Action" event featured interactive activities where citizens learned about health, received themed gifts, and engaged in various functional areas, including a large lung-clearing device that attracted many participants [2] - Medical experts provided insights on the relationship between influenza and lung health, symptom recognition, and scientific prevention methods, while free consultations were offered to the public [2] - Participants could measure their lung capacity and function through the "One Breath Lung Challenge," and learn practical lung health maintenance methods through exercises that combine traditional and modern techniques [2] Group 2 - The core concept of the "Clear Lung Action" is based on Kunming Pharmaceutical Group's flagship product, "Kun Traditional Chinese Medicine Clear Lung Phlegm Pill," which has historical roots dating back to the Song Dynasty and is known for its efficacy in clearing lungs and relieving cough [3] - Kunming Pharmaceutical Group's subsidiary, Kun Traditional Chinese Medicine, is recognized as the "oldest pharmaceutical company" by Guinness World Records and has been awarded the "Chinese Time-Honored Brand" honor [3] - Yixintang, a leading retail pharmacy chain in China, operates over 11,230 stores and serves approximately 210 million customers annually, enhancing the reach of health education initiatives [3] Group 3 - The collaboration between leading pharmaceutical companies and large retail pharmacy chains is advancing health education from one-way communication to interactive engagement, emphasizing preventive health measures in the context of the "Healthy China" strategy [4] - The "Clear Lung Action" effectively integrates traditional Chinese medicine's preventive wisdom with contemporary health management practices to safeguard public respiratory health [4]

医疗ETF（159828）跟踪的是中证医疗指数（399989），该指数从沪深市场中选取医药卫生和药品零售 行业的上市公司证券作为指数样本，主要覆盖医疗器械、医疗服务及医疗研发外包等领域，以反映医疗 主题相关上市公司证券的整体表现。该指数成分股偏向中小市值，具有较高的成长性与波动性特征。 （文章来源：每日经济新闻） 国金证券表示，REDEMPLO获批，CNS领域突破，Arrowhead如箭在弦。小核酸领域领军公司 Arrowhead制药上周市值上涨16.6亿美元。2025年11月18日，公司的第一款小核酸产品Plozasiran获FDA 批准上市，这标志着公司步入商业化兑现的历史新阶段。同时，公司在研产品正在向更大患者市场的慢 病与中枢神经系统领域推进。 医疗ETF（159828）连续5日迎净流入，小核酸进军慢病，如箭在弦。 ...

央视网消息：据市场监管总局网站消息，为充分发挥典型案例的示范引领作用，助力经营主体合规发 展，市场监管总局在现有的经营者集中简易案件公示、附条件批准案件和禁止案件审查决定公告、无条 件批准案件列表公示等案件公开制度的基础上，进一步加大经营者集中审查案件公开力度，现选取3起 无条件批准的非简易案件典型案例予以公布。 本次公布的典型案例涉及不同交易类型与行业，如涉及工业气体领域横向集中的杭州市国有资本投资运 营有限公司收购浙江盈德控股集团有限公司股权案、涉及药品零售领域纵向集中的高济医药有限公司收 购天济大药房连锁有限公司等三家公司股权案等。公开这些典型案例有利于帮助企业进一步提高申报效 率和申报质量，为投资并购营造公开、透明、可预期的制度环境。 相关案例不是案件事实的完整复现，重点在于呈现反垄断执法机构在经营者集中审查实践中的关注要点 与竞争分析思路，包括案件程序的适用，控制权变化的认定，相关市场的界定，横向、纵向等关系的认 定，市场份额和市场集中度的估算，评估单边效应、协调效应、封锁效应的考虑因素，相关证据材料的 考量等，在参考使用上需要结合具体情境灵活运用。 典型案例1 杭州市国有资本投资运营有限公司收购浙 ...

Core Insights - The article highlights a significant inflow of 12 million units into the medical ETF (159865), indicating strong investor interest in medical assets [1] - Beijing has issued measures to promote the high-quality development of the medical device industry, focusing on various aspects such as clinical research support, application promotion, and international expansion [1] Industry Summary - The new policies aim to provide robust support for innovative medical device companies, addressing previous barriers to hospital access for new products and fostering a positive cycle between research and market [1] - The measures include financial support for qualifying innovative device enterprises, which is expected to enhance the innovation and development of medical consumables [1] - Policies related to international expansion are designed to reduce the cost burden of overseas registration for companies, particularly benefiting those seeking new market opportunities amid domestic procurement pressures [1] Company Summary - The medical ETF (159828) tracks the CSI Medical Index (399989), which selects listed companies in the pharmaceutical and healthcare sectors from the Shanghai and Shenzhen markets [1] - The index primarily covers areas such as medical devices, medical services, and medical research outsourcing, reflecting the overall performance of related listed companies [1] - The constituent stocks of the index tend to be small to mid-cap companies, characterized by high growth potential and volatility [1]

Core Viewpoint - Long Fung Group, a leading pharmacy chain in Hong Kong, has submitted a listing application to the Hong Kong Stock Exchange, with the exclusive sponsor being DBS Bank [1] Company Overview - Long Fung Group is the largest retail pharmacy in Hong Kong by retail sales, holding a market share of 5.2%, and is the second-largest retailer of health, medical, and beauty products with a market share of approximately 5.8% [1] - The company operates 29 physical retail stores in Hong Kong, with a total available floor area exceeding 123,000 square feet [1] - Long Fung's mobile application has over 200,000 members as of last November [1] Financial Performance - For the fiscal year ending March 2025, Long Fung reported a profit of HKD 170 million, a year-on-year increase of 17.92%, with revenues of HKD 2.46 billion, up 21.76% [1] - In the first quarter of the fiscal year 2026, ending June 30, the company achieved a profit of HKD 47.76 million, a year-on-year increase of over 131%, with revenues of HKD 697 million, a growth of 42.48%, primarily driven by same-store sales growth and contributions from new stores [1] Expansion Plans - The funds raised from the listing will be primarily used to expand and enhance the store and online sales network, as well as for recruitment and training, including plans to open 11 new stores [1]